@inproceedings{inproceedings, title  = {{Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA)}},

 url = {{}},

 year = {{2012}},

 month = {{5}},

 author = {{Sartor AO and Heinrich D and O'Sullivan JM and Fossa SD and Chodacki A and Wiechno PJ and Logue JP and Seke M and Widmark A and Johannessen DC and Nilsson S et al}},

 volume = {{30}},

 journal = {{JOURNAL OF CLINICAL ONCOLOGY}},

 issue = {{15}},

 note = {{Accessed on 2025/10/10}}}